A liver slice culture-based ex vivo assay to predict the outcome of antiviral therapy for chronic hepatitis C

Journal of Viral Hepatitis

Volumn 16, Issue 5, 2009, Pages 359-366

  Chang, M L ^a   Sung, K F ^a   Sheen, I S ^a   Lin, S M ^a   Yeh, Chau Ting ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Ex vivo; Hepatitis C virus; Peginterferon; Predictor; Ribavirin; Stepwise logistic regression

Indexed keywords

ALBUMIN; HEPATITIS C ANTIBODY; PEGINTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; ASSAY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG SUPPRESSION ASSAY; EX VIVO STUDY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE CULTURE; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS REPLICATION;

ADULT; ALBUMINS; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER; MALE; MIDDLE AGED; ORGAN CULTURE TECHNIQUES; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RNA, VIRAL;

EID: 63549108756     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2009.01090.x     Document Type: Article

References (26)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989 244 : 359 362.
2. Genesca J, Esteban JI, Alter HJ. Blood-borne non-A, non-B hepatitis: hepatitis C. Semin Liver Dis 1991 11 : 147 164.
3. Freeman AJ, Dore GJ, Law MG et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001 34 : 809 816.
4. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 1997 26 (3 Suppl. 1 34S 38S.
5. Balasekaran R, Bulterys M, Jamal MM et al. A case-control study of risk factors for sporadic hepatitis C virus infection in the southwestern United States. Am J Gastroenterol 1999 94 : 1341 1346.
6. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 982.
7. Papatheodoridis GV, Cholongitas E. Chronic hepatitis C and no response to antiviral therapy: potential current and future therapeutic options. J Viral Hepat 2004 11 : 287 296.
8. Lee SS. Review article: indicators and predictors of response to anti-viral therapy in chronic hepatitis C. Aliment Pharmacol Ther 2003 17 : 611 621.
9. Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997 26 (3 Suppl. 1 122S 127S.
10. Castro FJ, Esteban JI, Juárez A et al. Early detection of nonresponse to interferon plus ribavirin combination treatment of chronic hepatitis C. J Viral Hepat 2002 9 : 202 207.
11. Rumi MG, Aghemo A, D'Ambrosio R et al. Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study. Antivir Ther 2007 12 : 1033 1040.
12. Jessner W, Stauber R, Hackl F et al. Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection. J Viral Hepat 2003 10 : 37 42.
13. Ferenci P. Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies. J Antimicrob Chemother 2004 53 : 15 18.
14. Yeh CT, Hwang DR, Lai HY, Hsu JT. Inhibition of authentic hepatitis C virus replication by sodium stibogluconate. Biochem Biophys Res Commun 2003 310 : 537 541.
15. Hwang DR, Lin RK, Leu GZ et al. Inhibition of hepatitis C virus replication by antimonial compounds. Antimicrob Agents Chemother 2005 49 : 4197 4202.
16. Hwang DR, Tsai YC, Lee JC et al. Inhibition of hepatitis C virus replication by arsenic trioxide. Antimicrob Agents Chemother 2004 48 : 2876 2882.
17. Yeh CT, Hsu CW, Chang ML et al. A novel ex vivo assay of interferon-based suppression, to predict the outcome of antiviral therapy for hepatitis C. J Infect Dis 2006 193 : 1365 1370.
18. Yeh CT, Lu SC, Tseng IC et al. Antisense overexpression of BMAL2 enhances cell proliferation. Oncogene 2003 22 : 5306 5314.
19. Yeh CT, Lai HY, Chen TC, Chu CM, Liaw YF. Identification of a hepatic factor capable of supporting hepatitis C virus replication in a nonpermissive cell line. J Virol 2001 75 : 11017 11024.
20. Akuta N, Suzuki F, Suzuki Y et al. Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: virological features of IFN-resistant cases with hepatocyte steatosis. J Med Virol 2005 75 : 550 558.
21. Soffredini R, Rumi MG, Parravicini ML et al. Serum levels of hepatitis C virus core antigen as a marker of infection and response to therapy. Am J Gastroenterol 2004 99 : 1738 1743.
22. Enomoto N, Sakuma I, Asahina Y et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996 334 : 77 81.
23. Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998 282 : 103 107.
24. Sentjens RE, Weegink CJ, Beld MG, Cooreman MC, Reesink HW. Viral kinetics of hepatitis C virus RNA in patients with chronic hepatitis C treated with 18 MU of interferon alpha daily. Eur J Gastroenterol Hepatol 2002 14 : 833 840.
25. Fukutomi T, Nakamuta M, Fukutomi M et al. Decline of hepatitis C virus load in serum during the first 24 h after administration of interferon-beta as a predictor of the efficacy of therapy. J Hepatol 2001 34 : 100 107.
26. Ekins S. Past, present, and future applications of precision-cut liver slices for in vitro xenobiotic metabolism. Drug Metab Rev 1996 28 : 591 623.